mat (2)

SAMHSA FAQs: Provision of methadone and buprenorphine for the treatment of Opioid Use Disorder in the COVID-19 emergency

In response to the Novel Coronavirus Disease (COVID-19) pandemic, SAMHSA is providing answers to Frequently Asked Questions regarding the provision of methadone and buprenorphine for the treatment of Opioid Use Disorder for new and existing patients.

California Opioids: MAT expansion + new state opioid laws

The California MAT Expansion project

https://www.dhcs.ca.gov/individuals/Pages/State-Targeted-Response-to-Opioid-Crisis-Grant.aspx

The California MAT Expansion Project aims to increase access to MAT, reduce unmet treatment need, and reduce opioid overd

Hello, you need to enable JavaScript to use The NIC Collaboration Hub.

Please check your browser settings or contact your system administrator.

Opioid Prevention

mat (2)

SAMHSA FAQs: Provision of methadone and buprenorphine for the treatment of Opioid Use Disorder in the COVID-19 emergency

California Opioids: MAT expansion + new state opioid laws

The California MAT Expansion project

The California MAT Expansion Project aims to increase access to MAT, reduce unmet treatment need, and reduce opioid overd

Note: this page contains paid content.